SEC Company Response from Tvardi Therapeutics, Inc. (TVRD) (CIK 0001346830) (TVRD) — May 13, 2015
Tvardi Therapeutics, Inc. (TVRD) (CIK 0001346830)
Date: May 13, 2015 · CIK: 0001346830 · Accession: 0001193125-15-185159
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-203072
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Cara Therapeutics, Inc. (the “Company”) Form S-3, File No. 333-203072
Dear Ms. Berenshteyn:
The Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. (Eastern time) on Wednesday, May 13, 2015, or as soon as practicable thereafter.
The Company further acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
CARA THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Correspondence Letter
May 13, 2015
VIA EDGAR
Ms. Alla Berenshteyn
Securities and Exchange
Commission
Division of Corporation Finance
100 F Street,
N.E.
Washington, DC 20549
Re:
Cara Therapeutics, Inc. (the “Company”)
Form S-3, File No. 333-203072
Dear Ms. Berenshteyn:
The Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to
cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. (Eastern time) on Wednesday, May 13, 2015, or as soon as practicable thereafter.
The Company further acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the
disclosure in the filing; and
•
the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
CARA THERAPEUTICS, INC.
By:
/s/ Josef Schoell
Josef Schoell
Chief Financial Officer
cc: Darren K. DeStefano, Cooley LLP